glp-1 agonists and sglt2 inhibitors APhA 2025: Receptor vs Show Varied Benefit for Cardiovascular Outcomes in Patients With Diabetes GLP-1 Agonists vs. SGLT2 Inhibitors:

In the month of May, 849 effective leads generated, majority of the patients call the practices new patient number

& Rendell, M

[DOI] [PubMed] [Google Scholar] 200.Nagasawa T., et al

placebo for 26 weeks and demonstrated a greater efficacy in terms of reduction of body weight and waist circumference (WC) in the liraglutide group [54,55,56]

Marys Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 3 Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea Correspondence to Hun-Sung Kim, MD Department of Medical Informatics, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea Email: [email protected] Copyright 2023 Korean Society of Cardiovascular Disease Prevention

Prescribing information (Eli Lilly, 2025)